Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Merck
Harvard Business School
Mallinckrodt
Medtronic

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,320,969

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,320,969 protect, and when does it expire?

Patent 7,320,969 protects SEASONIQUE and is included in one NDA.

This patent has forty patent family members in twenty-two countries.

Summary for Patent: 7,320,969
Title:Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Abstract:This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
Inventor(s): Bell; Robert G. (Palm Harbor, FL), Ben-Maimon; Carole (Merion, PA), Iskold; Beata (Livingston, NJ)
Assignee: Duramed Pharmaceuticals, Inc. (Cincinnati, OH)
Application Number:10/309,313
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,320,969
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 7,320,969

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva Branded Pharm SEASONIQUE ethinyl estradiol; levonorgestrel TABLET;ORAL 021840-001 May 25, 2006 AB RX Yes Yes   Start Trial   Start Trial PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,320,969

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002348272   Start Trial
Australia 2008237614   Start Trial
Bulgaria 108736   Start Trial
Brazil 0214716   Start Trial
Canada 2468748   Start Trial
Canada 2655959   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Harvard Business School
Johnson and Johnson
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.